ALTO-100-211
What is the ALTO-100-211 trial?
This study is looking at how well a new type of medication, ALTO‑100, works for treating bipolar depression, when used with a mood stabilizer and/or atypical antipsychotic.
You may be eligible to participate if
- You have a diagnosis of Bipolar
- At baseline, you are taking a mood stabilizer (lithium or lamotrigine or valproic acid or combination of lithium + lamotrigine or lithium + valporic acid) and/or taking an approved atypical antipsychotic medication (olanzapine, quetiapine, lurasidone, risperidone, ziprasidone, cariprazine, aripiprazole, lumateperone, and asenapine) for at least 6 weeks with no dose modifications in the past 2 weeks
- You are willing to comply with all study assessments and procedures
- You are not pregnant or breastfeeding at time of enrolment or throughout study
What does participating in ALTO-100-211 look like?
Taking part involves several tests and visits over 12-20 weeks, including a variety of lab and cognitive testing. The study has 3 parts:
- Screening period (about 6 weeks): The study team checks your health and makes sure the study is a good fit for you.
- Double‑blind treatment period (6 weeks): You will receive either the ALTO‑100 medication or a placebo. Neither you nor the study team will know which one you are taking during this phase.
- Optional open‑label period (7 weeks): If you finish the double‑blind phase, you can choose to continue in an open phase where everyone receives ALTO‑100.
How to take part
The ALTO-100-211 study is recruiting through the Care Pathway Enhancement (CaPE) Clinic at Cumbria Northumberland Tyne and Wear NHS Foundation Trust. The CaPE clinic offers appointments to people over the age of 18 with a mood disorder (depression or bipolar disorder) who are open to the possibility of participating in research, and who may be eligible for an ongoing trial, such as ALTO-100-211.
You can self-refer to the CaPE Clinic by completing a short Microsoft Forms form here. You can specify your interest in ALTO-100-211 via this form. Or you can be referred by a healthcare professional such as your GP. The CaPE Clinic can also be contacted on CaPE@cntw.nhs.uk
Or if you would like to ask a member of the study team more information about ALTO-100-211, you can email Clinical Studies Officer emily.clare@cntw.nhs.uk
More about CaPE